?? for dr. young

kz · 07-14-2004, 08:17 AM

dr. young , hi, i have a question regarding dr. huang oeg human trial. as far as i know (have read), he has done more than 400 operations and more or less the results and the effect of only oeg transplant operation are known to him by now.my question is this: scientifically and logically, what stops dr huang from adding at least one more compond to the oeg transplant operation to see what kind of results he get? (componds like what miami project used or nogo, chondro..abc, ngf, etc).is it the possible bad side effect from adding another compond?it seems like some of these componds are being used for so long.
what was the logic, reasons and basis (animal studies) for him to go ahead and do oeg transplant on human?what stops him from using the same logic, reason and basis and add another compond to oeg? aren't there enough combination animal treatment trials data (in database) to let him add another compond to the oeg?since he is already doing human trial, i thought may be it is possible that by adding just another compond to oeg he might get a result muchh greater than he is getting now. I appreciate your comment and explaination.

[This message was edited by kz on 07-14-04 at 12:35 PM.]

[This message was edited by kz on 07-14-04 at 01:02 PM.]

Wise Young · 07-14-2004, 10:46 AM

kz,

I think that people are getting the wrong impression of how easy it will be to do combination therapies in patients. Take, for example, the recent study that the Bunge laboratory reported: Schwann cell transplants, rolipram, and db cAMP injection into the spinal cord. Nobody, to my knowledge, has ever injected dibutyryl cAMP into the spinal cords of humans and certainly not in combination with rolipram or with cell transplants. It is not clear what it would do to olfactory ensheathing glia. So, we are working very hard to replicate that study but using olfactory ensheathing glia instead of Schwann cells.

The other combination is chondroitinase and GDNF plus Schwann cells, reported by Xiao Ming Xu's group. In animals, it has become clear that the chondroitinase loses its activity pretty quickly and the animals must get repeated injections of the chondroitinase. It is unclear how this should be done in humans and how long the chondroitinase can and should be injected into the spinal cord. Again, we are studying this in the laboratory right now.

Finally, it is important that Dr. Huang get the followup data on more patients for longer periods. At the present, he has obtained 6-12 month followup studies on only 10-20% of his patients. It has been very frustrating for him (and me) because he does not have the resources to do the followup on the patients. I have been working hard to help set up funding mechanism for following up his patients. Even people from the U.S. who have gone to China, have not obtained pre-operative and post-operative examinations by experienced physiatrists.

Wise.

07-14-2004, 08:17 AM	#1
kz Senior Member Join Date: Mar 2004 Posts: 170	?? for dr. young dr. young , hi, i have a question regarding dr. huang oeg human trial. as far as i know (have read), he has done more than 400 operations and more or less the results and the effect of only oeg transplant operation are known to him by now.my question is this: scientifically and logically, what stops dr huang from adding at least one more compond to the oeg transplant operation to see what kind of results he get? (componds like what miami project used or nogo, chondro..abc, ngf, etc).is it the possible bad side effect from adding another compond?it seems like some of these componds are being used for so long. what was the logic, reasons and basis (animal studies) for him to go ahead and do oeg transplant on human?what stops him from using the same logic, reason and basis and add another compond to oeg? aren't there enough combination animal treatment trials data (in database) to let him add another compond to the oeg?since he is already doing human trial, i thought may be it is possible that by adding just another compond to oeg he might get a result muchh greater than he is getting now. I appreciate your comment and explaination. [This message was edited by kz on 07-14-04 at 12:35 PM.] [This message was edited by kz on 07-14-04 at 01:02 PM.]

Thread Tools
Show Printable Version Email this Page
Display Modes
Switch to Linear Mode Hybrid Mode Switch to Threaded Mode

07-14-2004, 10:46 AM	#2
Wise Young Administrator Join Date: Jul 2001 Location: New Brunswick, NJ, USA Posts: 37,975	kz, I think that people are getting the wrong impression of how easy it will be to do combination therapies in patients. Take, for example, the recent study that the Bunge laboratory reported: Schwann cell transplants, rolipram, and db cAMP injection into the spinal cord. Nobody, to my knowledge, has ever injected dibutyryl cAMP into the spinal cords of humans and certainly not in combination with rolipram or with cell transplants. It is not clear what it would do to olfactory ensheathing glia. So, we are working very hard to replicate that study but using olfactory ensheathing glia instead of Schwann cells. The other combination is chondroitinase and GDNF plus Schwann cells, reported by Xiao Ming Xu's group. In animals, it has become clear that the chondroitinase loses its activity pretty quickly and the animals must get repeated injections of the chondroitinase. It is unclear how this should be done in humans and how long the chondroitinase can and should be injected into the spinal cord. Again, we are studying this in the laboratory right now. Finally, it is important that Dr. Huang get the followup data on more patients for longer periods. At the present, he has obtained 6-12 month followup studies on only 10-20% of his patients. It has been very frustrating for him (and me) because he does not have the resources to do the followup on the patients. I have been working hard to help set up funding mechanism for following up his patients. Even people from the U.S. who have gone to China, have not obtained pre-operative and post-operative examinations by experienced physiatrists. Wise.